Equity Profile

ABBV

AbbVie Inc.

Health CareBiotechnology$438.2B

Apr29Wed

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:47 AM EDT

AbbVie Misses on EPS, Stock Up 0.0%

Metric	Actual	Expected	Surprise
EPS	$2.65	$2.69	+1.30%
Revenue	N/A	$14.7B	N/A

management commentary, guidance changes, and full analysis available with Pro.

AbbVie Misses on EPS, Stock Up 0.0%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$2.65	$2.69	+1.30%
Revenue	N/A	$14.7B	N/A

Management Commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism despite missing EPS expectations. They emphasized their commitment to innovation and future growth.

Management acknowledged the challenges in meeting EPS expectations but expressed confidence in long-term growth.

They highlighted ongoing investments in research and development as a key focus area moving forward.

What It Means

AbbVie's earnings report shows a slight miss on EPS, which may raise concerns among investors. However, the stock reaction remained flat, indicating that the market may have already priced in these expectations. Management's focus on long-term growth and R&D investments suggests they are positioning the company for future success, even amidst current challenges.

Company Snapshot

AbbVie Inc. is a global biopharmaceutical company focused on developing innovative therapies for complex diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps gauge the company's financial health.

$2.69

Revenue

Total revenue reflects the company's ability to generate sales and is crucial for assessing growth.

$14.7B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

AbbVie Inc. is a global biopharmaceutical company focused on developing innovative therapies for complex diseases. Operating in the Health Care sector, AbbVie is known for its strong portfolio of medications, particularly in immunology, oncology, and neuroscience, making it a significant player in the biotechnology industry.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+1.22%

Avg Stock Reaction

+1.54%

Last Quarter Recap

In Q4 2025, AbbVie reported an EPS of $2.71, surpassing estimates by 2.03%. However, the stock dropped by 3.79% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect AbbVie to report solid earnings this quarter, with a consensus EPS of $2.69 and revenue of $14.7 billion. Investors are keen to see if the company can maintain its growth trajectory amid competitive pressures.

Bull Case

If AbbVie beats earnings expectations and provides positive guidance, it could signal strong demand for its products, leading to a potential stock rally.

Bear Case

Conversely, if AbbVie misses earnings estimates or fails to provide reassuring guidance, it may raise concerns about its growth prospects, resulting in a decline in stock price.

Key Metrics to Watch

EPS

$2.69

Earnings per share is a key indicator of profitability and helps gauge the company's financial health.

Revenue

$14.7B

Total revenue reflects the company's ability to generate sales and is crucial for assessing growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will AbbVie achieve an EPS of $2.69 or higher?

This figure is crucial as it directly impacts investor confidence and stock performance.

What are the revenue projections for AbbVie's key products?

Understanding revenue sources will help gauge the company's growth potential and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate AbbVie's ability to maintain revenue growth due to recent product launches that have not been fully factored into earnings estimates.

Supporting Evidence

AbbVie has a strong track record of beating EPS estimates, with a 75% success rate in the last eight quarters.

The options market is pricing a larger move than historical averages, indicating heightened expectations.

Recent insider selling could suggest confidence in the company's future performance despite the sales.

Key Risk

If revenue from key products exceeds $14.8 billion, it could challenge the cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching AbbVie's ability to meet or exceed earnings expectations, which could significantly influence stock performance.

Bull Confirmed If

Achieving an EPS of $2.69 or better would confirm strong operational performance.

Bear Confirmed If

An EPS below $2.57 would raise concerns about AbbVie's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±4.73%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±4.7% while ABBV has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

26.0%

Calls (750K)P/C Ratio: 1.10Puts (582K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AbbVie beats expectations, history suggests a potential stock increase of around +1.56%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of approximately -2.37%, reflecting investor disappointment and concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on sales performance for key drugs like Humira and Rinvoq.
2Any new product announcements or pipeline developments.
3Management's outlook on market competition and pricing pressures.
4Insights into cost management strategies and operational efficiency.
5Guidance on future earnings and revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

AbbVie Inc. is a global biopharmaceutical company focused on developing innovative therapies for complex diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps gauge the company's financial health.

$2.69

Revenue

Total revenue reflects the company's ability to generate sales and is crucial for assessing growth.

$14.7B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+1.22%

Avg Stock Reaction

+1.54%

Last Quarter Recap

In Q4 2025, AbbVie reported an EPS of $2.71, surpassing estimates by 2.03%. However, the stock dropped by 3.79% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If AbbVie beats earnings expectations and provides positive guidance, it could signal strong demand for its products, leading to a potential stock rally.

Bear Case

Conversely, if AbbVie misses earnings estimates or fails to provide reassuring guidance, it may raise concerns about its growth prospects, resulting in a decline in stock price.

Key Metrics to Watch

EPS

$2.69

Earnings per share is a key indicator of profitability and helps gauge the company's financial health.

Revenue

$14.7B

Total revenue reflects the company's ability to generate sales and is crucial for assessing growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will AbbVie achieve an EPS of $2.69 or higher?

This figure is crucial as it directly impacts investor confidence and stock performance.

What are the revenue projections for AbbVie's key products?

Understanding revenue sources will help gauge the company's growth potential and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate AbbVie's ability to maintain revenue growth due to recent product launches that have not been fully factored into earnings estimates.

Supporting Evidence

AbbVie has a strong track record of beating EPS estimates, with a 75% success rate in the last eight quarters.

The options market is pricing a larger move than historical averages, indicating heightened expectations.

Recent insider selling could suggest confidence in the company's future performance despite the sales.

Key Risk

If revenue from key products exceeds $14.8 billion, it could challenge the cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching AbbVie's ability to meet or exceed earnings expectations, which could significantly influence stock performance.

Bull Confirmed If

Achieving an EPS of $2.69 or better would confirm strong operational performance.

Bear Confirmed If

An EPS below $2.57 would raise concerns about AbbVie's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±4.73%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±4.7% while ABBV has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

26.0%

Calls (750K)P/C Ratio: 1.10Puts (582K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AbbVie beats expectations, history suggests a potential stock increase of around +1.56%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of approximately -2.37%, reflecting investor disappointment and concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on sales performance for key drugs like Humira and Rinvoq.
2Any new product announcements or pipeline developments.
3Management's outlook on market competition and pricing pressures.
4Insights into cost management strategies and operational efficiency.
5Guidance on future earnings and revenue expectations.